220,970 Shares in Neumora Therapeutics, Inc. $NMRA Acquired by Nuveen LLC

Key Points

• Nuveen LLC has acquired a new position in Neumora Therapeutics, purchasing 220,970 shares valued at approximately $221,000, bringing their total ownership to 0.14%.
• Other institutional investors, such as Lunate Capital Ltd and XTX Topco Ltd, also made significant investments in Neumora during the same quarter, indicating growing interest in the company.
• Neumora Therapeutics reported an EPS of ($0.33) for the last quarter, surpassing analysts' expectations, while the stock has a current average target price of $7.14.

Nuveen LLC acquired a new position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 220,970 shares of the company's stock, valued at approximately $221,000. Nuveen LLC owned approximately 0.14% of Neumora Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of NMRA. CWM LLC raised its position in Neumora Therapeutics by 7,124.4% in the 1st quarter. CWM LLC now owns 25,213 shares of the company's stock valued at $25,000 after buying an additional 24,864 shares during the last quarter. Aigen Investment Management LP purchased a new stake in shares of Neumora Therapeutics in the first quarter valued at about $36,000. Virtu Financial LLC bought a new position in shares of Neumora Therapeutics during the first quarter valued at about $40,000. Invesco Ltd. boosted its holdings in Neumora Therapeutics by 151.1% during the first quarter. Invesco Ltd. now owns 123,655 shares of the company's stock worth $124,000 after purchasing an additional 74,406 shares during the last quarter. Finally, Rafferty Asset Management LLC bought a new stake in Neumora Therapeutics in the 4th quarter worth about $185,000. Institutional investors own 47.65% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Mizuho lifted their target price on shares of Neumora Therapeutics from $4.00 to $5.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 16th. Three analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Neumora Therapeutics has an average rating of "Hold" and a consensus price target of $7.14.

Neumora Therapeutics Stock Performance

NMRA traded up $0.03 during midday trading on Thursday, reaching $1.66. The company had a trading volume of 314,451 shares, compared to its average volume of 375,571. Neumora Therapeutics, Inc. has a 12-month low of $0.61 and a 12-month high of $17.19. The business has a 50-day moving average price of $1.63 and a two-hundred day moving average price of $1.16. The stock has a market cap of $268.84 million, a PE ratio of -1.06 and a beta of 2.91. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.54 and a current ratio of 10.54.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.05. On average, sell-side analysts expect that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.